Pacira BioSciences, Inc. (PCRX) - Net Assets
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has net assets worth $671.97 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.24 Billion) and total liabilities ($572.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pacira BioSciences, Inc. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $671.97 Million |
| % of Total Assets | 54.02% |
| Annual Growth Rate | 30.52% |
| 5-Year Change | -5.11% |
| 10-Year Change | 216.52% |
| Growth Volatility | 135.35 |
Pacira BioSciences, Inc. - Net Assets Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Pacira BioSciences, Inc. (PCRX) total market value.
Annual Net Assets for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual net assets of Pacira BioSciences, Inc. from 2008 to 2025. Also explore Pacira BioSciences, Inc. (PCRX) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $693.11 Million | -10.95% |
| 2024-12-31 | $778.35 Million | -10.55% |
| 2023-12-31 | $870.13 Million | +12.27% |
| 2022-12-31 | $775.01 Million | +6.11% |
| 2021-12-31 | $730.41 Million | +17.87% |
| 2020-12-31 | $619.69 Million | +74.59% |
| 2019-12-31 | $354.94 Million | +10.50% |
| 2018-12-31 | $321.23 Million | +14.94% |
| 2017-12-31 | $279.48 Million | +27.63% |
| 2016-12-31 | $218.98 Million | +0.27% |
| 2015-12-31 | $218.39 Million | +27.61% |
| 2014-12-31 | $171.15 Million | +314.91% |
| 2013-12-31 | $41.25 Million | -37.36% |
| 2012-12-31 | $65.86 Million | +36.43% |
| 2011-12-31 | $48.27 Million | +199.76% |
| 2010-12-31 | $-48.38 Million | -110.83% |
| 2009-12-31 | $-22.95 Million | -406.40% |
| 2008-12-31 | $7.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pacira BioSciences, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12126700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.01% |
| Other Comprehensive Income | $4.33 Million | 0.62% |
| Other Components | $888.06 Million | 128.13% |
| Total Equity | $693.11 Million | 100.00% |
Pacira BioSciences, Inc. Competitors by Market Cap
The table below lists competitors of Pacira BioSciences, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fujian Yuanli Active Carbon Co Ltd
SHE:300174
|
$988.63 Million |
|
Wonders Information
SHE:300168
|
$988.70 Million |
|
IRB-Brasil Resseguros S.A.
SA:IRBR3
|
$988.71 Million |
|
National Presto Industries Inc
NYSE:NPK
|
$988.84 Million |
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
$988.17 Million |
|
Bright Real Estate Group Co Ltd
SHG:600708
|
$988.14 Million |
|
Guangdong Silvere Sci and Tech
SHE:300221
|
$987.88 Million |
|
Malakoff Corporation Bhd
KLSE:5264
|
$987.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pacira BioSciences, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 778,348,000 to 693,111,000, a change of -85,237,000 (-11.0%).
- Net income of 7,034,000 contributed positively to equity growth.
- Share repurchases of 148,328,000 reduced equity.
- Other comprehensive income increased equity by 3,984,000.
- Other factors increased equity by 52,073,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.03 Million | +1.01% |
| Share Repurchases | $148.33 Million | -21.4% |
| Other Comprehensive Income | $3.98 Million | +0.57% |
| Other Changes | $52.07 Million | +7.51% |
| Total Change | $- | -10.95% |
Book Value vs Market Value Analysis
This analysis compares Pacira BioSciences, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.77x to 1.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $14.18 | $25.12 | x |
| 2009-12-31 | $-40.04 | $25.12 | x |
| 2010-12-31 | $-2.81 | $25.12 | x |
| 2011-12-31 | $2.94 | $25.12 | x |
| 2012-12-31 | $2.17 | $25.12 | x |
| 2013-12-31 | $1.24 | $25.12 | x |
| 2014-12-31 | $4.85 | $25.12 | x |
| 2015-12-31 | $5.29 | $25.12 | x |
| 2016-12-31 | $5.88 | $25.12 | x |
| 2017-12-31 | $7.02 | $25.12 | x |
| 2018-12-31 | $7.85 | $25.12 | x |
| 2019-12-31 | $8.55 | $25.12 | x |
| 2020-12-31 | $14.19 | $25.12 | x |
| 2021-12-31 | $16.01 | $25.12 | x |
| 2022-12-31 | $16.65 | $25.12 | x |
| 2023-12-31 | $16.74 | $25.12 | x |
| 2024-12-31 | $16.83 | $25.12 | x |
| 2025-12-31 | $15.39 | $25.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pacira BioSciences, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.97%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.82x
- Recent ROE (1.01%) is above the historical average (-50.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -558.91% | -300.62% | 0.28x | 6.75x | $-42.61 Million |
| 2009 | 0.00% | -211.30% | 0.34x | 0.00x | $-29.41 Million |
| 2010 | 0.00% | -186.44% | 0.22x | 0.00x | $-22.31 Million |
| 2011 | -89.76% | -276.17% | 0.14x | 2.35x | $-48.15 Million |
| 2012 | -79.39% | -133.77% | 0.35x | 1.70x | $-58.87 Million |
| 2013 | -154.93% | -74.70% | 0.50x | 4.12x | $-68.03 Million |
| 2014 | -8.01% | -6.94% | 0.61x | 1.91x | $-30.83 Million |
| 2015 | 0.85% | 0.75% | 0.64x | 1.78x | $-19.98 Million |
| 2016 | -17.33% | -13.73% | 0.71x | 1.79x | $-59.85 Million |
| 2017 | -15.25% | -14.87% | 0.46x | 2.25x | $-70.56 Million |
| 2018 | -0.15% | -0.14% | 0.49x | 2.15x | $-32.59 Million |
| 2019 | -3.10% | -2.62% | 0.51x | 2.34x | $-46.51 Million |
| 2020 | 23.48% | 33.87% | 0.34x | 2.06x | $83.55 Million |
| 2021 | 5.75% | 7.75% | 0.26x | 2.84x | $-31.06 Million |
| 2022 | 2.05% | 2.39% | 0.40x | 2.17x | $-61.59 Million |
| 2023 | 4.82% | 6.22% | 0.43x | 1.81x | $-45.06 Million |
| 2024 | -12.79% | -14.20% | 0.45x | 2.00x | $-177.39 Million |
| 2025 | 1.01% | 0.97% | 0.57x | 1.82x | $-62.28 Million |
Industry Comparison
This section compares Pacira BioSciences, Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $354,496,597
- Average return on equity (ROE) among peers: -93.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | $671.97 Million | -558.91% | 0.85x | $988.42 Million |
| Aurora Cannabis Inc (ACB) | $3.83 Million | -248.34% | 2.53x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $166.09 Million | -138.50% | 2.72x | $143.73 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.65 Million |
| Akebia Ther (AKBA) | $394.76 Million | -70.84% | 0.95x | $240.07 Million |
| Alkermes Plc (ALKS) | $1.82 Billion | 13.28% | 0.39x | $6.85 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $3.29 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $26.20 Million | 12.60% | 0.10x | $272.61 Million |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more